The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma
Cancer Immunology, Immunotherapy · 2023-12 · 72 (12) · 3953-3969
DOI: 10.1007/s00262-023-03568-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 02.11.2023. Verfasst von Liqiu Kou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in humans, which is prone to recurrence and metastasis and has a poor prognosis. The occurrence and progression of HCC are closely related to immune elimination, immune homeostasis, and immune escape of the immune system. In recent years, immunotherapy, represented by immune checkpoint inhibitors (ICIs), has shown powerful anti-tumor capabilities in HCC patients. However, there are still some HCC patients who cannot benefit from ICIs treatment due to their innate or acquired drug resistance. Therefore, it is of great practical significance to explore the possible mechanisms of resistance to ICIs in HCC and to use them as a target to design strategies to reverse resistance, to overcome drug resistance in HCC and to improve the prognosis of patients. This article summarizes the possible primary (tumor microenvironment alteration, and signaling pathways, etc.) and acquired (immune checkpoint upregulation) resistance mechanisms in patients with HCC treated with ICIs, and based on this, discusses the status and effectiveness of combination drug strategy to reverse drug resistance, to provide a reference for subsequent related studies and decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China.
- School of Pharmacy, Southwest Medical University, Luzhou, China.
- Department of Hepatobiliary Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
- Department of Traditional Chinese Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China. ljadoctor@swmu.edu.cn.
- Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China. lylapothecary@swmu.edu.cn.
Zitieren
APA
Kou, L., Xie, X., Chen, X., Li, B., Li, J., & Li, Y. (2023). The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 72(12), 3953-3969. https://doi.org/10.1007/s00262-023-03568-3
Vancouver
Kou L, Xie X, Chen X, Li B, Li J, Li Y. The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma. Cancer Immunology, Immunotherapy. 2023;72(12):3953-3969. doi:10.1007/s00262-023-03568-3
BibTeX
@article{Kou2023,
author = {Kou, Liqiu and Xie, Xiaolu and Chen, Xiu and Li, Bo and Li, Jun and Li, Yaling},
title = {The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma},
journal = {Cancer Immunology, Immunotherapy},
year = {2023},
volume = {72},
number = {12},
pages = {3953--3969},
doi = {10.1007/s00262-023-03568-3}
}
EUVIMED